Floatz logo

Irinotecan

Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma

National Cancer Institute (NCI)Small moleculePhase 1Dormant
CC
44/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
81/ 100

Competitive context

20 Active assets in the Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
Alliance for Clinical Trials in Oncology
Phase 4BB
Cyclophosphamide
City of Hope Medical Center
Phase 2BB
DEXAMETHASONE
Zhengzhou University
Phase 4BB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
National Cancer Institute (NCI)
Phase 2BB
CIS-DIAMMINEDICHLOROPLATINUM II
Zhengzhou University
Phase 4BB

View all 35 →

Same molecule, other indications

Irinotecan is also rated in:

rectal cancerDormant
BBB
Indicative ·
78 / 100
View asset →
exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
Peritoneal NeoplasmsDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →